APLS - Apellis Pharmaceuticals, Inc.
| Previous Close | 28.90 |
| Open | 28.17 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 29.04 - 29.74 |
| 52 Week Range | 11.45 - 29.89 |
| Volume | 219,001 |
| Avg. Volume | 387,618 |
| Market Cap | 1.87B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.32 |
| Earnings Date | Jul 31, 2019 - Jul 31, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.43 |
- GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on August 12, 2019, the Company approved the grant of equity awards to three new employees with a grant date of August 12, 2019, as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and material to each employee's acceptance of employment with the Company. The employees received, in the aggregate, options to purchase 27,300 shares of Apellis common stock.
- American City Business Journals
CEO Survey: Cedric Francois, Apellis Pharmaceuticals
Cedric Francois is CEO and co-founder of Apellis Pharmaceuticals. In a recent survey with Business First, he shared some insights on his industry, the Louisville community and what keeps him up at night.
- GlobeNewswire
Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results
Completed Enrollment in Phase 3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Head-to-Head Study in Patients Treated with Eculizumab; Top-line Data Anticipated in December 2019.
- American City Business Journals
Apellis expands C-suite amid plans to double its workforce
The company's first female chief officer has worked with several life sciences companies throughout her career.
- American City Business Journals
Apellis Pharmaceuticals expanding product pipeline
Gene therapies treat conditions caused by problems in people's DNA, the building blocks of life. Apellis' second experimental compound could make them more effective.
- GlobeNewswire
Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer
Apellis Pharmaceuticals, Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Lucia Celona as Chief People Officer. Prior to joining Apellis, Celona worked at Bioverativ where as the Chief HR and Communications Officer she was instrumental in the formation of the company, directing matters relating to talent, organization design, culture, public affairs and employee communications. “We are thrilled to welcome Lucia to Apellis’ leadership team.
- GlobeNewswire
Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies
CRESTWOOD, Ky. and WALTHAM, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the control of the complement system, today announced its plans to develop APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus (AAV) vector administration for gene therapies. APL-9, an investigational drug, is a pegylated synthetic cyclic peptide designed to modulate the complement cascade centrally at C3. “Gene therapies are among the most exciting medical advancements of our time.
- Motley Fool
3 Biotech Stocks That Could Double Your Money
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
- TheStreet.com
Apellis Pharma Climbs on Upgrade to Overweight at JP Morgan
JP Morgan analysts see promising opportunities in Apellis's later-stage drug to treat the blood disorder PNH.
- GlobeNewswire
Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the completion of enrollment for its PEGASUS Phase 3 trial assessing the safety and efficacy of APL-2 (pegcetacoplan) in patients with paroxysmal nocturnal hemoglobinuria (PNH) compared to eculizumab (Soliris™). The study enrolled 80 patients, approximately half of whom were transfusion dependent. Apellis expects to release top-line data in December 2019.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 9 percentage points since the end of the third quarter of 2018 as investors worried over the possible ramifications of rising interest rates and escalation of the trade war with China. The hedge funds and institutional investors we track typically invest more […]
- GlobeNewswire
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel.
- Simply Wall St.
Investors Who Bought Apellis Pharmaceuticals (NASDAQ:APLS) Shares A Year Ago Are Now Up 10%
If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...
- GlobeNewswire
Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results
Resumed Dosing in Phase 3 Geographic Atrophy Program Announced Innovative Collaboration & Financing with SFJ Pharmaceuticals® Cash Position of $288.2 Million at.
- American City Business Journals
Apellis executives got a raise 2018 and will get another in 2019
Two Apellis Pharmaceuticals Inc. executives saw the value of their total compensation more than double in 2018 from the year before, according to a proxy filing from the company. Crestwood, Ky.-based Apellis (Nasdaq: APLS) cites several accomplishments, including progress on the company's clinical trials for its signature treatment, for the increases in compensation.
